NasdaqHealth CarePharmaceutical PreparationsMORRISTOWN, NJ

Whitehawk Therapeutics, Inc. WHWK

Ask your AI

Estimated market cap $180.57M59.01M shares, shares as of Nov 5, 2026CIK 1422142

Insider trades, 12 mo

0 buys · 14 sells

$2.58M sold, open market

Congress trades, 24 mo

—

No disclosed trades

13F holders, Q3 2026

18.8% of shares · 26 added

13F holders

…

Lobbying, 12 mo

—

No lobbying filings

Federal contracts, 12 mo

—

None matched

Ask your AI:

Latest 10-Q

Q3 2026

What changed in Whitehawk Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Filed Nov 9, 2026 · Quarter ended Sep 30, 2026

Compared with the 10-Q for the quarter ended Jun 30, 2026. Sections compared: management's discussion, risk factors, legal proceedings and controls and procedures.

Read the 10-Q on sec.gov ↗Filing index ↗

Latest 10-Q

What changed in Whitehawk Therapeutics, Inc.'s latest quarterly report, compared with the one before.

Loading…

Insider trades

14 in 12 mo

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

No open-market insider trades reported since Apr 16, 2026. Insiders have two business days to file.

Recent insider trades

Scott M. Giacobello CHIEF FINANCIAL OFFICER	Apr 16 Form 4 ↗	Sale	−$584.8K 141,600 sh @ $4.13	-35.2%
Scott M. Giacobello CHIEF FINANCIAL OFFICER	Apr 15 Form 4 ↗	Sale	−$297.2K 77,000 sh @ $3.86	-29.3%
Bryan Ball See remarks	Apr 14 Form 4 ↗	Sale	−$336.6K 92,460 sh @ $3.64	-32.1%
Bryan Ball See remarks	Apr 13 Form 4 ↗	Sale	−$91.3K 26,389 sh @ $3.46	-21.8%
Bryan Ball See remarks	Apr 10 Form 4 ↗	Sale	−$22.6K 6,596 sh @ $3.43	-20.8%

All WHWK insider trades →Planned sales (Form 144): see notices

Insider trades

Open-market trades from Form 4. 10b5-1 marks a plan set in advance.

Loading…

13F holders

11.11M shares

52 funds report WHWK. Values checked against market prices.

Funds own 76% of shares (Q2 2026)

78 funds hold the stock.

Q3 2026: 19% · 5,560 of ~8,900 funds reported so far

Q2 202562%
Q3 202561%
Q4 202570%
Q1 202675%
Q2 202676%
Q3 2026 (so far)19%

Q3 2026. 13 new, 26 added to, 3 trimmed, 40 exited since Q2 2026.

Top 13F holders
#
1	BlackRock, Inc. 13F ↗	2.59M	$9.7M	+34.7%
2	Siren, LLC 13F ↗	2.34M	$8.8M	unchanged
3	Vanguard Capital Management LLC 13F ↗	1.47M	$5.5M	+5.6%
4	Geode Capital Management, LLC 13F ↗	1.06M	$4.0M	+17.3%
5	Renaissance Technologies LLC 13F ↗	663,922	$2.5M	+60.4%
6	State Street Corp 13F ↗	591,672	$2.2M	+52.9%
7	Acadian Asset Management LLC 13F ↗	436,226	$1.6M	+155.3%
8	Vanguard Portfolio Management LLC 13F ↗	296,030	$1.1M	+35.0%
9	Vanguard Fiduciary Trust Co 13F ↗	283,605	$1.1M	+14.9%
10	Squarepoint Ops LLC 13F ↗	206,513	$776.5K	New

One of these funds reports its values in thousands of dollars; its figures are shown in dollars.

Download CSV Every fund that holds WHWK, not only these ten. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

13F holders

Funds that report this stock, checked against market prices.

Loading…

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

No recent congressional trades for this company.

Trades by members of Congress

Disclosed in dollar ranges, up to 45 days after the trade.

Loading…

Lobbying

What Whitehawk Therapeutics, Inc. and its lobbying firms report each quarter.

No recent lobbying filings for this company.

Lobbying

What Whitehawk Therapeutics, Inc. and its lobbying firms report each quarter.

Loading…

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Funds holding the stock

Shares they report

Funds holding the stock by quarter

Q3 2021	32	—	11.10M	$324.1M
Q4 2021	45	+13	12.21M	$294.8M
Q1 2022	54	+9	12.73M	$219.2M
Q2 2022	68	+14	13.24M	$159.3M
Q3 2022	68	0	15.07M	$212.1M
Q4 2022	76	+8	15.30M	$192.2M
Q1 2023	70	-6	14.35M	$106.6M
Q2 2023	67	-3	14.30M	$100.8M
Q3 2023	73	+6	14.73M	$75.3M
Q4 2023	65	-8	13.30M	$26.9M
Q1 2024	60	-5	14.15M	$33.1M
Q2 2024	65	+5	11.47M	$16.7M
Q3 2024	52	-13	11.98M	$24.7M
Q4 2024	53	+1	14.97M	$47.2M
Q1 2025	50	-3	31.81M	$56.4M
Q2 2025	39	-11	29.43M	$54.6M
Q3 2025	41	+2	28.83M	$54.3M
Q4 2025	48	+7	32.98M	$79.2M
Q1 2026	62	+14	35.19M	$122.7M
Q2 2026	78	+16	43.24M	$198.0M
Q3 2026	52	-26	11.11M	$41.8M

Each point is a quarter-end, from Q3 2021 to Q3 2026. A fund's 13F lists its long positions in US-listed securities as of the last day of the quarter and arrives up to 45 days later, so each point shows holdings at quarter-end, not on the day they were reported.

Common shares only; options and bonds are left out. When a fund amends a report, the amended version is the one counted.

The history follows the company's current CUSIP number (00032Q104). If the company's shares were ever re-issued under a different CUSIP, the quarters before the change are not part of this series, so the first point (Q3 2021) can be later than the stock's first appearance in 13F reports.

Share counts are adjusted for stock splits; none took place between these quarters. Values are in dollars as reported at the time and are not adjusted.

A quarter appears once our daily update has built its summary. If a summary cannot be built, older reports are kept and the chart shows the quarters it has until the next update repairs it.

Institutional ownership over time

How many funds reported holding the stock at the end of each quarter, and how many shares they held between them.

Loading…

More filings and data

Each opens the table.

Ownership stakes5 in 12 mo 8-K events2 in 90 days PatentsNone on record Short interestFINRA · updated Oct 15 Planned insider salesForm 144 · 4 in 12 mo Executive pay3 fiscal years Wikipedia attentionNone on record SEC enforcementNone on record Clinical trials2 active IPO history1 registration Ownership stakes…8-K events…Patents…Short interest…Planned insider sales…Executive pay…Wikipedia attention…SEC enforcement…

About the company

The basics from the company’s SEC registration.

Legal name: Whitehawk Therapeutics, Inc.
Address: 2 HEADQUARTERS PLAZA, EAST BUILDING, 11TH FLOOR, MORRISTOWN, NJ 07960
Phone: 551-321-2234
Fiscal year ends: Dec 31
Filer category: Non-accelerated filer, smaller reporting company
Incorporated in: DE
Listed as: WHWK (Nasdaq)
Former names: Aadi Bioscience, Inc. (until 2025); Aerpio Pharmaceuticals, Inc. (until 2021); ZETA ACQUISITION CORP II (until 2017)
SEC filings: All filings on SEC EDGAR ↗

About the company

The basics from the company’s SEC registration.

Loading…

$3.06−$0.01 (−0.33%) Nov 13 close

1M3M1Y

Oct 13, 2026Low $2.89 · High $3.46Nov 13, 2026

Aug 13, 2026Low $2.89 · High $5.08Nov 13, 2026

Nov 13, 2025Low $1.99 · High $5.10Nov 13, 2026

Congress purchase Congress sale Insider sale over $1M

Adjusted for stock splits; not for dividends. Where prices come from.

Live chart

Intraday and historical prices from TradingView. Quotes may be delayed.

Loading chart…

Information, not investment advice. Company matching is automatic; check the source before relying on one row.